# Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Source: https://onco.cc/trials/nct07136181/  
OnCo record `nct07136181` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. in uveal melanoma, run by Novelwise Pharmaceutical Corporation, now recruiting.

## Summary

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma is a phase 1/2 interventional study registered as NCT07136181 by Novelwise Pharmaceutical Corporation, with 36 participants planned, started 2025-11-20 and due to reach its primary completion in 2028-03-28. Interventions recorded: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers..

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07136181
- Phase: 1/2
- Setting: A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
- Sponsor: Novelwise Pharmaceutical Corporation
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07136181: https://clinicaltrials.gov/study/NCT07136181

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07136181.json